Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Rogaratinib in Japanese patients with advanced solid tumors
NCT02592785Phase 1Completed
- Sponsor
- Bayer
- Start
- Dec 2015
- Primary completion
- Feb 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of rogaratinib in solid tumor (2 cohorts), sponsored by Bayer. Primary endpoints: Number of Treatment Emergent Adverse Events, Intensity of Treatment Emergent Adverse Events and 4 more. Started Dec 2015; status: completed.
02
Drugs
rogaratinib
03
Conditions
solid tumor
Beyond the preview
Go deeper on NCT02592785.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02592785.